Results were presented today at the American Society for Mass Spectrometry Conference from a study conducted including samples of patients who had been seriously ill with COVID-19, of individuals who had an asymptomatic course of COVID-19, and of other patients, as additional references, who had been diagnosed with either bacterial sepsis, common-cold coronavirus, or who were healthy controls. The study results show that there are statistically highly significant glycoproteomic profiles differentiating severe from asymptomatic COVID-19. Of interest, while a number of glycoproteomic attributes were shared between patients suffering from symptomatic COVID-19 and bacterial sepsis, likely representative of a systemic inflammatory response, a subset of glycoproteomic biomarkers were specific to severe COVID-19, potentially providing insights into specific pathological consequences of, or a particular predisposition for, a severe course of the infection.

“These results highlight yet another clinically important use application of perspectIV™ and the potential of glycoproteomics to discover new biomarkers and novel insights into pathobiology,” said Aldo Carrascoso, CEO and co-founder of InterVenn.

To find out more about InterVenn Biosciences or partnership opportunities, visit https://intervenn.com. For all media inquiries about InterVenn Biosciences, please contact Andrea Vuturo at press@venn.bio

About InterVenn Biosciences

InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker discovery and interrogation platform based on artificial intelligence-empowered mass spectrometry for next-gen precision medicine. The company is working on developing novel predictive tests in a range of indications, including ovarian, pancreatic, liver, prostate, lung, kidney and other cancers, as well as on tests for treatment response prediction and monitoring of treatment efficacy, and disease progression.